Using animal-derived constituents in anaesthesia and surgery: the case for disclosing to patients by Rodger, D et al.
Title page: 
1. Daniel Rodger (corresponding author) 
London South Bank University, Department of Allied Health Sciences, School of Health and                         
Social Care, 103 Borough Road, London, SE1 0AA, England 
daniel.rodger@lsbu.ac.uk  
2. Bruce P. Blackshaw 
University of Birmingham, Department of Philosophy, School of Philosophy, Theology and                     
Religion, Birmingham, England 
bblackshaw@gmail.com   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Using animal-derived constituents in anaesthesia and surgery: the case for disclosing                     
to patients 
  
Keywords: Animal-derived products, informed consent, vegetarianism, veganism,             
principlism, Montgomery, paternalism, anaesthesia, surgery, dressings  
 
Abstract: 
Background 
Animal-derived constituents are frequently used in anaesthesia and surgery, and patients                     
are seldom informed of this. This is problematic for a growing minority of patients who may                               
have religious or secular concerns about their use in their care. It is not currently common                               
practice to inform patients about the use of animal-derived constituents, yet what little                         
empirical data does exist indicates that many patients want the opportunity to give their                           
informed consent. 
 
Discussion 
First we review the nature and scale of the problem by looking at the groups who may have                                   
concerns about the use of animal-derived constituents in their care. We then summarise                         
some of the products used in anaesthesia and surgery that can contain such constituents,                           
such as anaesthetic drugs, surgical implants and dressings. Finally, we explore the problem                         
of animal-derived constituents and consent using Beauchamp and Childress’ four principles                     
approach, examining issues of autonomy, beneficence, nonmaleficence and justice. 
 
Summary 
Disclosing the use of animal-derived constituents in anaesthesia and surgery is warranted                       
under Beauchamp and Childress’ four principles approach to the problem. Although there                       
exist systemic and practical challenges to implementing this in practice, the ethical case for                           
doing so is strong. The Montgomery ruling presents additional legal reason for disclosure                         
because it entails that patients must be made aware of risks associated with their treatment                             
that ​they​ attach significance to.  
 
Background 
Providing healthcare in a culturally diverse society can involve a number of unique                         
challenges and compromises. The problem of animal-derived products in healthcare has                     
received some attention in the literature [1,2,3]. However, very few clinicians remain aware                         
of the scale of the problem, and even fewer have considered how it could be navigated in a                                   
way that respects the rights and interests of patients. When so many individuals and groups                             
differ on fundamental concepts, what constitutes care for one patient could be interpreted                         
as harm by another. Some of these fundamental disagreements surround the ethical                       
permissibility of products utilised in healthcare that contain an animal-derived constituent. 
 
Patients with certain religious and secular beliefs may express concerns about the use of                           
animal-derived constituents in their care, and in some cases, this can result in a patient                             
refusing certain kinds of treatment [1,4,5,6]. The area of perioperative care is notably                         
problematic because of the broad range of products employed that may contain                       
animal-derived constituents, such as anaesthetic drugs, surgical implants and dressings.                   
An increasing number of individuals would like to and may even expect to be informed of                               
any animal-derived constituents that could be used in their care. 
 
The United Kingdom (UK) represents a diverse and multicultural population who hold a                         
variety of religious and secular beliefs about the permissibility of using animals for food,                           
clothing, research or medical products, and this population is increasing. Between the 2001                         
and 2011 censuses, the Muslim population in England and Wales increased by 1.2 million,                           
and from 3 percent to 5 percent of the total population [7]. For Muslims, products                             
containing animal-derived constituents are unlikely to be ​halal​—compatible with Islamic                   
dietary laws. Furthermore, research commissioned by The Vegan Society found that about                       
1% or over 500,000 of the over-15 UK population now follow a vegan diet which amounts                               
to more than a 300% increase since 2006—a significant proportion of who avoid                         
non-dietary animal products [8]. This steep increase in both the Muslim and vegan                         
populations implies that the number of individuals who might object to the use of                           
animal-derived products used in healthcare is growing rapidly. This raises some significant                       
ethical and practical issues for clinicians, the most pertinent being deciding what                       
information should or should not be disclosed to patients about the products being used to                             
treat them.  
 
The importance of disclosure has been recently highlighted by the Montgomery v                       
Lanarkshire Health Board [2015] case, which has transformed UK law on informed consent                         
[9]. With regard to informing the patient of any material risks involved in their treatment, the                               
Montgomery ruling shifts the emphasis from what clinicians would agree is reasonable, to                         
what a reasonable patient would expect to know. The ruling means that clinicians must                           
communicate relevant information to a patient, even if its disclosure could lead the patient                           
to make a choice that may not be in their best interest [10]. Patients are entitled to make                                   
decisions that a clinician disagrees with, unless they lack capacity to make an informed                           
choice [11]—even if a clinician is concerned that disclosing certain information could cause                         
psychological harm or lead a patient to refuse life-saving treatment [12].  
  
In this article, we explore which patients may wish to be informed about the use of                               
animal-derived constituents in their anaesthetic and surgical care, and then describe some                       
of the products that may contain them. We then consider some of the ethical issues                             
associated with using these products in anaesthesia and surgery. Employing Beauchamp                     
and Childress’ influential four principles of bioethics—autonomy, beneficence,               
nonmaleficence and justice—we examine the case for disclosing this information to patients                       
and the potential challenges of doing so [13]. 
 
Who has concerns about the use of animal-derived constituents? 
 
In 2017, the Vegan Society sent a letter to the UK’s Secretary of State for Health, detailing                                 
their concerns about the use of animal-derived constituents in healthcare, and the current                         
lack of transparency on the labelling of medicines [14]. Understandably, the growing                       
number of vegetarians and vegans want to know if the drugs they might be prescribed                             
contain animal-derived constituents. Individuals are increasingly restricting their               
consumption and use of animal-derived products for a number of reasons: perceived health                         
benefits, environmental concerns, ethical reasons such as promoting animal welfare, and                     
objections to the intentional killing of non-human animals [15]. It has been estimated that                           
between 3-7% of the UK population are vegetarian [16]. 
 
Importantly, not all vegetarians would necessarily object to the use of drugs, dressings or                           
implants that have animal-derived constituents. Merely being vegetarian does not                   
necessarily entail objecting to the use of animal-derived products, since some reasons for                         
being vegetarian may not extend beyond dietary preferences [2]. This is in contrast with                           
vegans who typically will not eat or use dairy products, eggs or other animal-derived                           
products. Vegans are much more likely to have concerns about any animal-derived                       
products that may be used in their care, and will want to be fully informed. Many will wish to                                     
avoid animal-derived products as far as possible and opt for an alternative, should one                           
exist. Charlotte Houltram, a vegan anaesthetist, has stated that achieving an animal-derived                       
product free anaesthetic can be practicable and offers helpful guidance on how to do so                             
[17]. Houltram notes that because all drugs currently in use in the UK have been tested on                                 
animals during their development, none of them can be considered to be fully vegan.                           
Consequently, their use will always involve a degree of compromise. 
  
There is also a more sizeable population who potentially may object to the use of                             
animal-derived products in anaesthesia and surgery for religious reasons. In one survey of                         
13 representative religious leaders, 10 (77%) expressed concerns about the use of                       
biological products—including those with animal-derived constituents—in healthcare and               
thought that informed consent should be obtained from patients [18]. A subsequent study                         
by Eriksson et al. explored which religious groups object to the use of drugs, implants and                               
dressings containing animal-derived constituents [19]. It was discovered that a number of                       
the world’s largest religions objected to the use of some animal-derived products. For                         
example, Muslims—Sunni and Shiite—in the study objected to the use of any                       
porcine-containing products. In Islam, pork and its by-products are considered ‘haram’                     
which means forbidden and so for some Muslims the use of porcine-containing products is                           
impermissible, even if the alternative non-porcine containing product—should one                 
exist—meant that healing and recovery was delayed or it was more expensive [18,20]. For                           
some Muslims, what would be unlawful to consume can also be considered unlawful in the                             
context of healthcare [21]. Nevertheless, Islam is not homogenous and there remains no                         
definitive consensus regarding the use of products that contain an animal-derived                     
constituent [20,22]. Individual Muslims may therefore have differing beliefs and ways to                       
navigate such conflicts should be considered [21]. 
 
Hindus from one of the major traditions known as Vaishnavism objected to the use of                             
drugs, implants and dressings that contain porcine and bovine constituents [19]. This view                         
may not necessarily be representative of all of the traditions within Hinduism, although the                           
majority are vegetarians and avoid egg. However, the use of any animal-derived products                         
may be problematic for many Hindus, with many categorically rejecting their use [1,23]. The                           
Christian, Jewish and Buddhist leaders contacted by Eriksson et al. had no objections to                           
any animal-derived products [19]. However, all of the religious groups that objected to the                           
routine use of animal-derived products stated that they would be permissible providing (1)                         
there was no viable alternative and (2) they were required for emergency treatment [19].                           
However, what is classed as emergency treatment can be ambiguous. Some kinds of                         
surgical procedure containing animal-derived products may not be life-saving, but they may                       
have a substantial positive impact on a patient’s long-term quality of life and general                           
wellbeing. 
  
Neither religious or secular groups are homogeneous in their views on the use of                           
animal-derived products used in their care. Consequently, there is considerable diversity of                       
opinion, and membership of a particular group does not necessarily dictate an individual’s                         
convictions. The increase in the number of religious and secular individuals who might be                           
concerned about the use of animal-derived constituents indicates that this is an issue                         
healthcare professionals can no longer afford to ignore. 
 
Drugs, dressings and implants containing animal-derived constituents 
 
A number of products used in anaesthesia and surgery contain animal-derived constituents                       
that some patients may object to, were they to know. What is particularly problematic is                             
that patients who may have concerns are rarely informed that some of the products utilised                             
in their care may contain animal-derived constituents. These include a number of                       
anaesthetic drugs, surgical implants and dressings. For instance, some drugs contain                     
animal-derived excipients (substances that do not contribute to the therapeutic action),                     
which can make up 90% of the formulation [24]. These cannot always be easily identified                             
because there is currently no legal requirement for them to be included on the packaging. 
 
In one study it was discovered that of the 100 most prescribed drugs in primary care in the                                   
UK, 74 contained an animal-derived ingredient (most commonly bovine and porcine                     
sources) [3]. This highlights the scale of the problem for religious and secular patients who                             
may object to the use of products with animal-derived constituents. For instance,                       
amoxicillin capsules can be prescribed postoperatively before discharge, yet they contain                     
porcine or bovine sourced gelatin, which is widely used to encapsulate medication [25].                         
Some capsules can be opened to avoid ingesting the gelatin, but this is not always                             
advisable, unless clearly stated on the patient information leaflet. However, amoxicillin in                       
oral suspension is suitable for vegans and is one alternative for patients who would prefer                             
to minimise their use of animal-derived constituents. 
 
The most commonly used induction agent in anaesthesia—Propofol—contains purified egg                   
phosphatide, which vegans would want to avoid, and as it is likely the eggs used are not                                 
free range, many vegetarians would similarly find its use problematic [17, 26]. Avoiding                         
Propofol is not an insurmountable problem and could be managed relatively easily by an                           
anaesthetist but it will depend on the kind of induction that is clinically indicated. There is a                                 
formulation of Propofol called Cleofol®, which is manufactured in India and does not                         
contain any egg phosphatide or other animal-derived constituents [27]. However, its use                       
has been associated with excessive pain on injection [28]. This may not be sufficient to rule                               
out the use of Cleofol® as a viable alternative for patients who wish to avoid animal-derived                               
constituents. After all, a well known side-effect of Propofol is pain on injection, which                           
occurs in 60% of untreated patients; pain on injection can be mitigated by using an                             
antecubital vein or pre-treatment with intravenous (IV) Lidocaine [29]. Moreover, Houltram                     
suggests that patients could avoid Propofol by opting for local or regional anaesthesia, or                           
where appropriate by using an induction agent that does not contain any animal-derived                         
constituents such as Thiopentone, or by having a gas rather than IV induction [17]. She                             
does note that having a gas induction may be contraindicated in some cases.  
 
Hydrocolloid dressings can contain porcine-derived gelatin and are routinely used for a                       
number of different types of hip and knee surgery [30,31]. Most commonly in the form of                               
DuoDERM® which can also be used to help secure endotracheal tubes (ETT) or                         
nasopharyngeal airways, and protect skin integrity in neonates and infants [32,33]. In a                         
study by Enoch et al. published in 2005, it was discovered that very few healthcare                             
professionals were aware of which commonly used dressings contained biological material,                     
and were therefore not necessarily in a position to inform patients [18]. Enoch et al.                             
subsequently recommended that hospitals, higher education institutions and product                 
manufacturers should take immediate action to ensure that healthcare professionals are                     
educated about the biological products they frequently use [18]. The lack of education and                           
easily available information creates a barrier to informing patients who might object to the                           
use of certain biological products, including those with animal-derived constituents.                   
However, there is little evidence to suggest that much has changed in more than a decade. 
 
There are also a number of surgical products or implants that could also be objectionable to                               
a number of patients. These include composite and biological mesh commonly used to                         
repair the abdominal wall during hernia surgery and in some types of colorectal surgery                           
[4,34]. They frequently use ingredients from porcine or bovine sources, and this information                         
is not always easily accessible. Biopolymer sutures can also contain animal-derived                     
constituents, including those from ovine and bovine sources [35]. Other types of surgical                         
products that can contain animal-derived constituents include orthopaedic spacers, heart                   
valves and haemostasis matrix [19]. 
 
This brief summary of animal-derived products used in anaesthesia and surgery shows that                         
clinicians are routinely using drugs, dressings and surgical implants that a sizable minority                         
of patients in the UK may have a material interest in being informed of. We are not                                 
suggesting that there are any easy answers: we are keenly aware of the existing systemic                             
obstructions, and some of the reasons clinicians may be hesitant to acknowledge that this                           
practice could be ethically problematic enough to warrant any serious concern. The health                         
service is already over-stretched, under-resourced, understaffed and many clinicians are                   
already struggling to provide patient care under those existing constraints. Nevertheless,                     
the General Medical Council’s guidance on personal beliefs and medical practice state that                         
when ‘...assessing what is of overall benefit to adult patients, you must take into account                             
their cultural, religious or other beliefs and values.’ [36]. In principle, it does not seem                             
unreasonable to us to conclude that this guidance implies that patients should be informed                           
about the use of animal-derived products in their care. Furthermore, surgical (and medical)                         
inpatients are routinely asked about their dietary requirements; there is no expectation that                         
they must self-declare that they require vegan, halal or kosher food. It seems inconsistent                           
to go to the effort and expense of respecting patient’s religious or secular dietary choices                             
and then use products in their care that many of them may feel as strongly about. Informing                                 
patients can therefore demonstrate a more holistic approach to their religious or secular                         
beliefs, rather than maintaining what could be interpreted as a paternalistic approach to the                           
issue. 
 
Applying the four principles approach 
 We indicated that Beauchamp and Childress’ four principles approach will be used to                         
examine the issue of disclosure of animal-derived products in perioperative care. We will                         
consider what each principle informs us about the problem, and attempt to weigh any                           
competing concerns that are uncovered. Beauchamp and Childress recommend a process                     
of deliberation to decide the relative weights of each norm in this context, so that balancing                               
judgements can be made if conflicts between principles are found when they are applied                           
[13]. Beauchamp and Childress offer some practical conditions for restricting balancing to                       
prevent the process from being too open-ended, such as requiring that any infringement of                           
a principle is the least possible infringement with no better alternative, and has realistic                           
prospects of achieving the objective [13]. 
 
Autonomy 
 
The first principle is respect for autonomy: acknowledging a patient’s right to make choices                           
based on their personal values and beliefs, the paradigmatic example being obtaining their                         
informed consent before treatment. One of the key elements of informed consent is                         
disclosure of relevant information, including ‘those facts or descriptions that patients or                       
subjects usually consider material in deciding to refuse or consent to the proposed                         
intervention or research’ [13]. Typically disclosure might involve factors such as risks and                         
benefits of a procedure, but Beauchamp and Childress also suggest disclosure should be                         
ideally tailored to ‘the specific informational needs of the individual person’, needs which                         
might include ‘unconventional beliefs’ [13]. Although only a small minority of the population                         
is vegan, there are also significant numbers of people who avoid certain animal-derived                         
foods for religious reasons, and there is widespread acceptance of disclosure of the use of                             
animal-derived products in the food industry. As already noted, it is common practice in UK                             
hospitals to request inpatient preferences for their dietary requirements, religious or                     
otherwise. 
 
It seems reasonable to inform patients of the use of animal-derived products in their                           
treatment, even if it is not possible to avoid their use. Although the recent Montgomery v                               
Lanarkshire Health Board [2015] case concerned clinical risks that could lead to patients                         
being harmed, it has established a precedent in the UK that the patient’s autonomy must be                               
respected—the patient must be made aware of material risks involved in a recommended                         
treatment as well as reasonable alternatives [9]. A risk is defined as material if the patient is                                 
likely to attach significance to this risk. Although in the context of the Montgomery case this                               
refers to risks of the medical procedure, the legal implications could be broader: arguably,                           
some patients could be harmed by being treated with animal-derived products if they have                           
strong moral or religious concerns and they later learn this has occurred. It is not for                               
clinicians to assess the significance of this risk on their patient’s behalf. Autonomy as                           
understood by Beauchamp and Childress entails that autonomous agents have the right to                         
act according to their values and beliefs [13]. If a clinician, for instance, knows that their                               
patient is Hindu, Muslim or vegan and fails to disclose the use of known animal-derived                             
products in their care, they may be disrespecting their patient’s autonomy. 
  
Do patients want to know this information? Respect for patient autonomy entails a                         
presumption that they do, and this has been reinforced by the Montgomery ruling. One                           
study from the United States (US) found that 84% of patients sampled were unaware that                             
over 1000 medications contain animal-derived constituents, and 63% wanted their                   
physicians to inform them about medications that contained these products [37]. This                       
provides empirical support for the claim that many patients would prefer to be informed                           
about the use of animal-derived constituents in their care. Interestingly, 70% of physicians                         
believed that providing their patients with this information was important, although                     
acknowledging this seldom lead to any changes in practice [37].  
 
The available evidence therefore indicates that a significant proportion of patients may want                         
this information disclosed to them, and given the importance of respect for patient                         
autonomy, this implies clinicians should not presume patients are uninterested but rather                       
ascertain if the use of animal-derived constituents is an issue for them. If so, they should, as                                 
far as possible, disclose the use of known animal-derived constituents in the patient’s care                           
to ensure their concerns are adequately catered for.  
 
Nonmaleficence 
 
The second principle is nonmaleficence, or the obligation not to inflict harm. According to                           
Beauchamp and Childress, harm is a thwarting, defeating, or setting back of some party’s                           
interests, and it is a prima facie principle that harmful actions must be sufficiently justified                             
[13]. While this commonly refers to physical harm, it also encompasses psychological                       
harms, which describes harms that can damage someone's psychological well-being. As                     
we indicated earlier, patients who may be concerned about the use of animal-derived                         
products in their care may consider that they have been psychologically harmed by not                           
having that information disclosed, and later learning they have been treated with                       
animal-derived products without their consent.  
 
Clinicians may consider such objections unconventional and obstructive, nevertheless,                 
harm can be very subjective and individualistic, and a clinician cannot presume any                         
resulting psychological harms would be trivial. Some vegetarians have described feeling                     
defiled at the thought of accidentally eating meat—anecdotal accounts describe such an                       
experience as ‘upsetting’—and so it is possible that failing to convey the use of an                             
animal-derived product could cause some degree of psychological harm [38,39]. Of course,                       
there may not be an alternative available, and it might be that a clinician considers it is                                 
justified in avoiding disclosing such information on the grounds that the patient may be                           
harmed if they refuse treatment.  
 
Potential harm from the patient’s refusal to accept treatment does not, however, seem                         
sufficient grounds to trump the combination of respect for patient autonomy and the                         
potential of later psychological harm. Failure to disclose the information on the basis that                           
the patient may make a decision that may not be in their interest is also not compatible with                                   
the Montgomery ruling. Unless the patient lacks capacity to make an informed choice, they                           
are entitled to refuse treatment if they believe that doing so would harm them, and even if                                 
doing so could lead to additional harms. We have already established that some patients                           
would object to the use of animal-derived products on religious or secular grounds, and it                             
seems likely they may be distressed to learn that products with these constituents were                           
used in their treatment, without their consent. Previous studies have identified that most                         
religions make a provision for the use of animal-derived product in an emergency—such as                           
life-prolonging surgery—or when all options for a clinically appropriate alternative have                     
been exhausted [1,19]. Nonmaleficence entails an obligation on clinicians to not impose                       
unnecessary harms; disclosing this information and gaining informed consent would be one                       
appropriate measure to avoid causing this kind of harm.  
 
Beneficence 
 
The principle of beneficence is closely related to nonmaleficence—the requirement to                     
contribute to the welfare of the patient (rather than harm them) by acting in their best                               
interest. It is important to consider if disclosure of the use of animal-derived products in                             
perioperative care will hinder patient welfare in some way. Obviously, the patient’s                       
treatment will be intended to benefit them, and it is possible that disclosing this information                             
could result in the patient refusing certain kinds of treatment. This is not just a theoretical                               
concern, as we noted in our introduction and discussed in the previous section.  
 
Sattar et al. describe four cases of medication non-adherence because of patients’                       
concerns about the use of certain animal-derived constituents that they believed to be                         
forbidden by their religion [40]. The patients only stopped taking their medication upon                         
finding out for themselves that it contained an animal-derived constituent. This led to either                           
worsening symptoms or relapses of their illness, and therefore a violation of the principle of                             
beneficence. Naively, withholding information might be thought to promote beneficence                   
because of the risk that some patients might decline treatment, but as these examples                           
show, some patients will investigate for themselves. Consequently, in these four cases of                         
medication non-adherence, the cause was the ​absence of disclosure and any conversation                       
about the contents of their medication prior to them being prescribed. All four patients were                             
subsequently provided with medication that did not contain an animal-derived constituent                     
and that satisfied their religious concerns. Beneficence in these cases would have been                         
achieved by disclosing this information, obtaining informed consent and amending the                     
medication in light of the patient’s religious beliefs.  
 
A UK questionnaire-based study of a mixed ethnicity inner-city population found that 43%                         
would avoid taking prescribed oral medication containing animal-derived ingredients, even                   
if there was no alternative treatment [41]. However, only 20% of those who preferred                           
vegetarian medication would ask the prescribing doctor if their medication contained                     
animal-derived ingredients. In the perioperative context, this highlights the importance of                     
communicating the possibility of animal-derived constituents being used to pre-empt these                     
concerns. This reinforces our earlier point regarding the potential harm that may eventuate                         
from the use of these constituents and the subsequent discovery of this by patients who                             
have strong religious or secular concerns with their use. 
  
There is still the issue of those patients who refuse treatment because of their convictions.                             
What course of action should be taken in these situations? It seems that there is an                               
obligation to ensure that alternative products are available where possible, at least for                         
commonly used products. In addition, patient disclosure should include variations in risks                       
and benefits incurred by using alternative products, and of course if a suitable alternative                           
exists and is available. Alternatives may not be available in emergencies, but we have noted                             
that religious groups and vegans may not object to the use of animal-derived constituents                           
in these situations in the absence of alternatives. Clinicians could also suggest, where                         
possible, that the patient discuss their concerns with a religious leader or secular authority.                           
In instances where a patient still refuses treatment because of unavoidable animal-derived                       
constituents, the patient’s wishes must be respected, provided they have capacity to make                         
an informed choice. 
 
Justice 
 
The final principle is justice, or the equitable distribution of goods—healthcare in this case.                           
We do not have space to discuss different principles of distributive justice that could be                             
employed, or whether there is a general right to healthcare and how it might be                             
implemented. For our purposes, we will assume that all patients deserve a minimum                         
standard of care, and the standard provided should be equivalent for each patient. In                           
practice, healthcare resources are always finite, demands are high, and consequently some                       
form of rationing and setting of priorities is always required. We can grant a prima facie                               
obligation to provide groups with certain religious or moral convictions about                     
animal-derived products with alternative products so they can receive equivalent care, but                       
budgetary limitations may constrain what can be offered. Constraints include the availability                       
and affordability of viable alternatives. Additionally, clinicians must be aware of these                       
alternatives, and be able to provide an assessment of their comparative efficacy and risks.                           
These constraints are considerable, and we must ask, to what extent should clinicians and                           
budgets be required to cater for patients with these convictions? The answer will be                           
dependent on each hospital’s budget, as well as the particular product involved—some                       
alternatives may be considerably more expensive than the equivalent animal-derived                   
product.  
 
An additional consideration, raised by Newson, is that some synthetic alternatives may have                         
greater efficacy than their equivalent [42]. This may mean that those patients with religious                           
and moral convictions about the use of animal-derived constituents may receive more                       
effective treatment than most patients, which seems unjust. The solution may be to provide                           
the synthetic version to all patients, but if this incurs significantly increased costs, it may                             
impact the provision of health services in other ways, and this may not be acceptable. Of                               
course, some non-animal-derived drugs may well be less effective than their equivalents,                       
but in these scenarios, the patient can be given the choice of either drug. 
  
For synthetic alternatives that prove too expensive, there is another approach that could be                           
considered. The minimum standard of care provided could exclude the provision of                       
synthetic drugs except where they incur similar costs, and patients whose convictions                       
require them to avoid animal-derived products could pay for these alternatives themselves,                       
either via a private health insurance policy designed for the purpose, or directly. If such a                               
policy is made widely known, over time those who hold such convictions could ensure they                             
make provision for this. 
  
What are the implications for disclosure? If, as a matter of policy, all clinicians were required                               
to disclose the use of animal-derived products to their patients, demand for alternatives                         
would increase and ultimately costs of these alternatives should decrease. In many                       
instances, synthetic alternatives could gradually replace certain animal-derived products for                   
all patients. This would, over time, make healthcare more accessible for those who hold                           
convictions about the use of animal-derived products. There are, however, a number of                         
complications that could ensue and which we now briefly explore. 
  
Challenges of disclosure 
 
We have sought here to make the ethical case for disclosure by considering the problem                             
using Beauchamp and Childress’ four principles approach. We will now review some of the                           
challenges that implementing it might generate in anaesthesia and surgery and beyond. It is                           
primarily problematic for a very practical reason: very few clinicians know whether or not                           
the 
drugs, surgical products and dressings they use contain any animal-derived constituents.                     
Additionally, as Tatham and Patel note, ‘information about animal derived products in                       
medicines is difficult to obtain, unclear, inconsistently reported, and sometimes incorrect’                     
[3]. Even clearer labelling, however, is not sufficient, as a comprehensive knowledge is also                           
required of what acceptable alternatives—should they exist—to each drug or product are                       
available, including efficacy and comparative risks.  
These types of systemic obstructions mean that clinicians are limited in what they can                           
actually promise a patient if they request that they want their care to be free of                               
animal-derived constituents. Clinicians can undertake to minimise their use, but will need to                         
communicate that insufficient information exists regarding the constituents in every product                     
they are using, and so it is possible that some products may still contain animal-derived                             
constituents. Any more than this may not be practicable until there has been significant                           
changes in product labelling. In some cases, surgeons will know that a product​—​such as a                             
biological surgical mesh containing porcine tissue—contains a constituent that a patient                     
may object to, and here we have established that patient concerns should be preempted                           
and informed consent should be obtained. In the context of anaesthesia it may be possible                             
for an anaesthetist to provide an ‘animal product free anaesthetic’ for patients, providing as                           
we have already discussed, that this is compatible with the kind of induction that is clinically                               
indicated [17]. This does still raise additional clinical concerns: it is conceivable that in trying                             
to meet the demands of patients who want an ‘animal product free anaesthetic’ that this                             
could lead to an increased risk of anaesthetic complications. For instance, the use of                           
Thiopentone in obstetrics has been associated with increased drug errors, and it is                         
relatively unfamiliar to the newer generation of anaesthetists who most frequently use                       
Propofol to induce patients [43]. 
 
The task of disclosure would be far easier if a legal requirement was introduced forcing the                               
declaration of inactive animal-derived constituents. A database of medicines licensed for                     
use in the UK already exists: the electronic Medicines Compendium (eMC) [44]. The eMC                           
contains a Summary of Product Characteristics (SmPC) for each medicine, which is                       
comprised of detailed information supplied by pharmaceutical companies, including active                   
and inactive constituents. This information is checked and approved by the UK or European                           
government agencies which licence medicines. It would be straightforward to augment the                       
existing data to indicate what constituents are animal-derived, and this would be a                         
significant step forward, at least for medicines. However, dressings and surgical implants                       
are not included in this compendium. Additionally, knowledge of acceptable                   
alternatives—should they exist—to each drug or product are required, including efficacy                     
and comparative risks. It seems feasible to include this information, although this would be                           
a more complex task. This would be broadly useful in healthcare far beyond anaesthesia                           
and surgery, and indeed, the case for disclosure presented here is likewise widely                         
applicable. 
 
A long-term solution, suggested by Tatham and Patel, would be to eliminate all                         
animal-derived constituents from all drugs and medical products [3]. This may seem                       
unlikely in the short-term, given the number of products that would require modification or                           
replacement, and the potential costs that would ensue. There are also no incentives for                           
medical and pharmaceutical companies to even consider this development. However, were                     
disclosure to be advocated, clinicians and patients could exert pressure on companies to                         
develop products that would alleviate their religious or secular concerns. Finally, an                       
important component of successful disclosure is improved education among healthcare                   
professionals regarding the use of animal-derived constituents. Higher education                 
institutions must consider their responsibility to educate healthcare professionals about the                     
ethical and legal issues surrounding the use of animal-derived products in healthcare.  
 
Conclusion 
 
The use of animal derived constituents in anaesthesia and surgery is of increasing interest                           
for a growing minority of patients, many of whom have religious or secular concerns about                             
their use. There has been a significant rise in the Muslim and vegan populations in the UK,                                 
and we have argued that existing research supports the contention that many of them                           
believe that they should be given the opportunity to provide informed consent. Clinicians                         
should expect to be increasingly confronted by patients who wish to know if any products                             
used in their care contain animal-derived constituents, and whether they can be avoided.                         
Clinicians must therefore consider how they will manage the concerns of such patients. 
 
We have applied Beauchamp and Childress’ four principles to this issue, and conclude that                           
they provide a strong case for disclosing the use of animal-derived constituents to patients                           
in anaesthesia and surgery, as well as other areas of healthcare. The importance of patient                             
autonomy provides the strongest argument for disclosure. The Montgomery ruling, while a                       
legal motivation rather than an ethical one, also emphasises the importance of patient                         
expectations about disclosure, and we have established that for many patients, the use of                           
animal-derived constituents is a significant issue.  
We acknowledge that full disclosure faces some practical difficulties at present: there are a                           
number of systemic obstructions that will need to be dealt with which will require significant                             
changes to the law, product development, education and clinical practice. Nevertheless,                     
our analysis strongly supports the contention that informed consent should be gained from                         
patients when animal-derived constituents will be used in their care, and that alternatives                         
should be sought where available and practicable.  
 
Declarations: 
Abbreviations 
Not applicable 
Ethics approval and consent to participate 
Not applicable. 
Consent for publication 
Not applicable. 
Availability of data and materials 
Not applicable. 
Funding 
No funding was obtained for this study 
Acknowledgements 
We would like to thank Louise Terry, Richard Playford, Charlotte Houltram and James Ip for                             
their helpful comments on an earlier draft. 
Competing interests 
The authors declare that they have no competing interests. 
Authors’ contributions 
DR and BB both drafted the article and have read and approved the final manuscript. 
 
References: 
  
1. Easterbrook C, Maddern G. Porcine and Bovine Surgical Products: 
Jewish, Muslim, and Hindu Perspectives. JAMA Surg. 2008; 143(4): 366-370.                   
https://doi.org/10.1001/archsurg.143.4.366​.  
2. Hoesli TM, Smith KM. Effects of Religious and Personal Beliefs on Medication Regimen                           
Design. Orthopedics. 2011; 34(4): 292-295.         
https://doi.org/10.3928/01477447-20110228-17​.  
3. Tatham KC, Patel KP. Suitability of common drugs for patients who avoid 
animal products BMJ. 2014; 348. ​https://doi.org/10.1136/bmj.g401​.  
4. Shiwani MH. Surgical meshes that contain bovine or porcine products should be labelled.                           
BMJ. 2011; 343.  ​https://doi.org/10.1136/bmj.d4625​.  
5. Corfield L, Granne I. Ethical and practical considerations in prescribing animal-derived                       
medication. Postgrad Med J. 2012; 88(1043): 497-498.             
http://dx.doi.org/10.1136/postgradmedj-2012-131053​.  
6. Ramaswamy KK, Kakodkar P. Animal products and Anaesthesia. Anaesth Intensive Care.                       
2006; 34(6):830-831. 
7. Office for National Statistics. Full story: What does the Census tell us about religion in                               
2011? 2013.  
https://www.ons.gov.uk/peoplepopulationandcommunity/culturalidentity/religion/articles/ful
lstorywhatdoesthecensustellusaboutreligionin2011/2013-05-16​. Accessed 27 Jan 2018.  
8. The Vegan Society. Find out how many vegans are in Great Britain. 2016.                           
https://www.vegansociety.com/whats-new/news/find-out-how-many-vegans-are-great-brit
ain​. Accessed 12 Sep 2018.  
9. Montgomery v Lanarkshire Health Board [2015] SC 11 [2015] 1 AC 1430.                         
http://www.bailii.org/uk/cases/UKSC/2015/11.html​.  Accessed 20 Jan 2019. 
10. Chan SW, Tulloch E, Cooper ES, Smith A, Wojcik W, Norman JE. Montgomery and                             
informed consent: where are we now? BMJ. 2017; 357. ​https://doi.org/10.1136/bmj.j2224​.  
11. Humphreys RA, Lepper R, Nicholson TRJ. When and how to treat patients who refuse                             
treatment. BMJ. 2014; 348. ​https://doi.org/10.1136/bmj.g2043​.  
12. Terry L, Deegan M. Informing clients of risk: Immediate implications of a landmark                           
supreme court decision. Br J Midwifery. 2015; 23(7): 516-521.                 
https://doi.org/10.12968/bjom.2015.23.7.516​.  
13. Beauchamp TL, Childress JF. Principles of Biomedical Ethics. 7th ed. New York: NY,                           
Oxford University Press; 2013. 
14. The Vegan Society. Letter to Jeremy Hunt. 2017.                 
https://www.vegansociety.com/sites/default/files/Letter%20to%20Jeremy%20Hunt.pdf​. 
Accessed 12 Sep 2018.  
15. Petti A, Palmieri B, Vadalà M, Laurino C. Vegetarianism and veganism: not only benefits                             
but also gaps. A review. Progress in Nutrition. 2017; 19(3): 229-242.                     
https://doi.org/10.23751/pn.v19i3.5229​.  
16. Radak T. Vegetarianism. In: Edelstein S, editor. Food Science: An Ecological Approach.                         
Burlington, Jones & Bartlett Learning; 2013. p. 277-304. 
17. Houltram C. What vegans should know pre-operatively. 2017.                 
https://www.vegansociety.com/whats-new/blog/what-vegans-should-know-pre-operatively
.  Accessed 27 Jan 2019. 
18. Enoch S, Shaaban H, Dunn K. Informed consent should be obtained from patients to                             
use products (skin substitutes) and dressings containing biological material. J Med Ethics.                       
2005; 31(1): 2-6. ​https://doi.org/10.1136%2Fjme.2003.005272​.  
19. Eriksson A, Burcharth J, Rosenberg J. Animal derived products may conflict with                         
religious patients' beliefs. BMC Med Ethics. 2013; 14: 48.                 
https://doi.org/10.1186/1472-6939-14-48​.  
20. Ogden J. Religious constraints on prescribing medication. Prescriber. 2016; 27(12):                     
47-51. ​https://doi.org/10.1002/psb.1524​.  
21. Sabir A, Yusuf A, Muhammed BJ. G496 Caring for body and soul – navigating religious                               
objections by muslim parents. Arch Dis Child. 2015; 100:A213.                 
http://dx.doi.org/10.1136/archdischild-2015-308599.449​.  
22. Wombwell E, Fangman MT, Yoder AK, Spero DL. Religious Barriers to Measles                         
Vaccination. J Community Health. 2015; 40(3): 597-604.             
https://doi.org/10.1007/s10900-014-9956-1​.  
23. Jenkins ED, Yip M, Melman L, Frisella MM, Matthews BD. Informed Consent: Cultural                           
and Religious Issues Associated with the Use of Allogeneic and Xenogeneic Mesh                       
Products. J Am Coll Surg . 2010; 210(4): 402-410.                 
https://doi.org/10.1016/j.jamcollsurg.2009.12.001​.  
24. Page A, Etherton-Beer C. Choosing a medication brand: Excipients, food intolerance                       
and prescribing in older people. Maturitas. 2018; 107: 103-109.                 
https://doi.org/10.1016/j.maturitas.2017.11.001​.  
25. Beddis HP. Pharmaceuticals: Animal ingredients. Br Dent J. 2016; 220 (11): 557.                         
https://doi.org/10.1038/sj.bdj.2016.391​.  
26. Aitkenhead AR. Intravenous Anaesthetic Agents. In: Aitkenhead A, Thompson J,                     
Rowbotham J, Moppett I, editors. Smith and Aitkenhead's Textbook of Anaesthesia.                     
London: Churchill Livingstone; 2013. p. 37-55. 
27. Munjal M, Sood D, Gupta VK, Singh A, Kaul TK. Use of vegetarian propofol in Jain                                 
community of India. Anaesthesia. 2003; 58(11): 1137.             
https://doi.org/10.1046/j.1365-2044.2003.03504.x​.  
28. Sood D, Tewari A, Katyal S, Narula N, Garg S, Kaul TK. Pain on injection of Cleofol®.                                   
Anaesthesia. 2005; 60(5): 521-2. ​https://doi.org/10.1111/j.1365-2044.2005.04207.x​.  
29. Jalota L, Kalira V, George E, Shi YY, Hornuss C, Radke O, Pace NL, Apfel CC.                                 
Prevention of pain on injection of propofol: systematic review and meta-analysis. BMJ.                       
2011; 342: d1110. https://doi.org/10.1136/bmj.d1110. 
30. Siddique K, Mirza S, Housden P. Effectiveness of hydrocolloid dressing in postoperative                         
hip and knee surgery: literature review and our experience. J Perioper Pract. 2011; 21(8):                           
275-278. ​https://doi.org/10.1177%2F175045891102100803​.  
31. Chowdhry M, Chen AF. Wound dressings for primary and revision total joint                         
arthroplasty. Ann Transl Med. 2015; 3(18): 268.             
https://doi.org/10.3978/j.issn.2305-5839.2015.09.25​.  
32. Lund CH, Kuller JM. Intergumentary System. In: Kenner C, Lott JW, editors.                         
Comprehensive Neonatal Care: An Interdisciplinary Approach. 5th ed. New York, Springer                     
Publishing Company; 2013. p. 299-333. 
33. Parhizkar N, Saltzman B, Grote K, Starr J, Cunningham M, Perkins J, Sie K.                             
Nasopharyngeal Airway for Management of Airway Obstruction in Infants with Micrognathia.                     
Cleft Palate Craniofac J. 2011; 48(4): 478-482. ​https://doi.org/10.1597%2F09-263​.  
34. FitzGerald JF, Kumar AS. Biologic versus Synthetic Mesh Reinforcement: What are the                         
Pros and Cons? Clin Colon Rectal Surg. 2014; 27(4) 140-148. doi:                     
10.1055/s-0034-1394155. ​https://doi.org/10.1055/s-0034-1394155​.  
35. Phelan PS, Council ML. Ethical considerations in the use of biopolymer sutures. J                           
Dermatolog Treat. 2018; ​https://doi.org/10.1080/09546634.2018.1514100​.  
36. General Medical Council. Personal beliefs and medical practice. 2013.                   
https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-doctors/personal-beliefs-an
d-medical-practice​.  Accessed 13 Sep 2018. 
37. Sattar SP, Ahmed MS, Madison J, Olsen DR, Bhatia SC, Ellahi S, Majeed F,                             
Ramaswamy S, Petty F, Wilson DR. Patient and Physician Attitudes to Using Medications                         
with Religiously Forbidden Ingredients. Ann Pharmacother. 2004; 38(11): 1830-1835.                 
https://doi.org/10.1345%2Faph.1E001​.  
38. Levy N. Vegetarianism: toward ideological impurity. In: Bramble B, Fischer B, editors.                         
The Moral Complexities of Eating Meat. New York, Oxford University Press; 2015.                       
P.172-184. 
39. Waters J. What Should You Do When You Accidentally Eat Meat At A Restaurant?                             
Vegan Life. 2017. ​https://www.veganlifemag.com/accidentally-eat-meat/​. Accessed 25 Jan             
2019. 
40. Sattar SP, Ahmed MS, Majeed F, Petty F. Inert medication ingredients causing                         
nonadherence due to religious beliefs. Ann Pharmacother. 2004; 38(4): 621-624.                   
https://doi.org/10.1345%2Faph.1D324​.  
41. Vissamsetti B, Payne M, Payne S. Inadvertent prescription of gelatin-containing oral 
medication: its acceptability to patients. Postgrad Med J. 2012; 88(1043): 499-502.                     
http://dx.doi.org/10.1136/postgradmedj-2011-130306​.  
42. Newson AJ. Clinical Ethics Committee Case 9: Should we inform our patient about                           
animal products in his medicine? Clinical Ethics. 2010; 5(1): 7-12.                   
https://doi.org/10.1258%2Fce.2009.009043​.  
43. Lucas DN, Yentis SM. Unsettled weather and the end for thiopental? Obstetric general                           
anaesthesia after the NAP5 and MBRRACE-UK reports. Anaesthesia. 2015; 70(4): 375–9.                     
https://doi.org/10.1111/anae.13034​.  
44. Electronic Medicines Compendium. ​https://www.medicines.org.uk/emc​. Accessed 4             
Feb 2019. 
 
 
 
 
 
 
 
 
